The FDA approved another Hybritech product.

The Food and Drug Administration’s approval of Hybritech’s second product that tests CEA in blood serum will maintain the San Diego-based biomedical firm’s campaign to secure a portion of the $25-million-per-year diagnostic market, company officials believe. That market now is controlled by Chicago-based Abbott Labs. CEA is found in patients with cancer of the colon, rectum, breast or lung. The FDA also approved Hybritech’s second rapid pregnancy test using a process that does not rely on instruments.